Brain Cancer
13 protocols meet the specified criteria.
-
20324
ON-TRK: PrOspective Non-Interventional Study in Patients with Locally Advanced or Metastatic TRK Fusion Cancer Treated with Larotrectinib -
A051901
Phase I Trial of Methotrexate, Rituximab, Lenalidomide, and Nivolumab (NIVO-MR2) Induction followed by Lenalidomide and Nivolumab Maintenance in Primary CNS Lymphoma -
A071601
Phase II Trial of BRAF/MEK Inhibitors in Papillary Craniopharyngiomas -
A071702
A Phase II Study of Checkpoint Blockade Immunotherapy in Patients with Somatically Hypermutated Recurrent Glioblastoma -
A151804
Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events -
COG-ACNS1422
A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients -
COG-ACNS1833
A Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine versus Selumetinib (NSC# 748727, IND# 77782) in Newly Diagnosed or Previously Untreated Low-Grade Glioma (LGG) not associated with BRAFV600E Mutations or Systemic Neurofibromatosis Type 1 (NF1) -
COG-ANBL00B1
Neuroblastoma Biology Studies -
EAY191
Molecular Analysis for Combination Therapy Choice (ComboMATCH) -
EF-32
A Pivotal Randomized, Open-Label Study of Optune (TTFields, 200KHZ) Concomitant with Radiation Therapy and Temozolomide for the Treatment of Newly Diagnosed Glioblastoma -
INTRAGO-II
A Multicenter Randomized Phase III Trial on Intraoperative Radiotherapy in Newly Diagnosed Glioblastoma Multiforme (INTRAGO II) -
S2013
Immune Checkpoint Inhibitor Toxicity (I-CHECKIT): A Prospective Observational Study -
WVU010320
A Phase I/II study of Radiation/Temozolomide and Immunotherapy with Daratumumab to Improve Antitumor Efficacy in Glioblastoma (PRIDE)